National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Aubagio® is indicated for the first line treatment of adult patients with relapsing remitting multiple sclerosis (MS).

Rapid Review

Commenced Completed Outcome
27/08/2013 20/09/2013 Full Pharmacoeconomic Evaluation recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
25/11/2013  19/06/2014 Reimbursement Not Recommended

The NCPE does not recommend reimbursement of teriflunomide (Aubagio®) at the current price.

Summary

05/09/2014

The HSE has approved reimbursement following confidential price negotiations.